Last reviewed · How we verify
Diabetes Medicines
Diabetes medicines work by improving blood glucose control through various mechanisms such as enhancing insulin secretion, increasing insulin sensitivity, or reducing hepatic glucose production.
Diabetes medicines work by improving blood glucose control through various mechanisms such as enhancing insulin secretion, increasing insulin sensitivity, or reducing hepatic glucose production. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | Diabetes Medicines |
|---|---|
| Also known as | Metformin, Sulfonylureas, Meglitinides, Thiazolidinediones, α-glucosidase inhibitor |
| Sponsor | Mackay Memorial Hospital |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Diabetes medicines encompass multiple drug classes with different mechanisms of action. Common approaches include stimulating pancreatic beta cells to release more insulin, improving the body's ability to use existing insulin, slowing carbohydrate digestion and absorption, or promoting glucose excretion through the kidneys. The specific mechanism depends on the individual agent within the diabetes medicine category.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Hypoglycemia
- Gastrointestinal disturbances
- Weight gain
- Lactic acidosis (metformin-related)
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- IRELAnD: Investigating the Role of Early Low-dose Aspirin in Diabetes (PHASE3)
- The Effect of Adiposity on Muscle and Microvascular Function in HFpEF
- Effects of Diabetic Educational Intervention and Dietary Supplements on Blood Glucose, Lipid Profile Levels, Body Mass Index, and Pain Management Among Adult Individuals With Painful Diabetic Peripheral Neuropathy. (NA)
- Turkish Validity and Reliability Study of Diabetes-Specific Nutrition Knowledge Questionnaire in Adolescents With Type 1 Diabetes
- Re-Engineered Discharge for Diabetes Care Transitions (NA)
- Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy (PHASE3)
- Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diabetes Medicines CI brief — competitive landscape report
- Diabetes Medicines updates RSS · CI watch RSS
- Mackay Memorial Hospital portfolio CI